Proposed USPTO Rules Likely to Cause Harm

July 11, 2024

Proposed USPTO Rules Threaten Innovation and Patent Integrity

The US Patent & Trademark Office (USPTO) has issued a Notice of Proposed Rulemaking (NPRM) regarding Terminal Disclaimer Practice to Obviate Nonstatutory Double Patenting. The intent is to make it cheaper and easier to strike down whole families of patents to prevent them “from potentially deterring competition.”



“BIO [Biotechnology Innovation Organization] believes that the proposed rule “is unsupported by the factual record, lacks legal authority, lacks a policy justification, is inconsistent with statutory and case law, and would cause extensive harm to the patent system,” says BIO’s comments.


Specific objections include:

  • The proposed rule assumes that many innovative products are protected by “too many” patents, but for drugs the average number of patents for products registered with the Food and Drug Administration is 3-5.
  • USPTO has no legal right to make such overarching changes to patent protections.
  • The proposed rule “would undermine the value of U.S. patents and discourage innovators from seeking U.S. patents on improvement inventions and follow-on technologies.”
  • It would raise the cost of patent examinations.


A group of five former USPTO Directors, Deputy Directors and Patent Commissioners sent a letter to current Director Kathi Vidal in opposition to the proposed NPRM rule package. Other experts like IPWatchdog Founder and CEO Gene Quinn called the NPRM “outrageously stupid,” noting that the law requires that patent validity be assessed claim by claim and that the judicially-created doctrine of double patenting lacks a proper basis in U.S. patent law. There are concerns shared broadly that adopting the proposed rules would increase uncertainty substantially for patent owners and wreak havoc in the bio-industry, especially for early-stage companies

RECENT ARTICLES

MichBio Hiring: Intern, Association Membership & Resource Analytics

April 15, 2025
MichBio seeks a highly motivated individual who can work creatively in a small team environment and assist in data mining, compilation, and research.

Bio Survey Underscores Impacts of Tariffs for Businesses

April 11, 2025
The Biotechnology Innovation Organization (BIO), of which MichBio is a state affiliate recently released the results of a survey of its members, noting that “U.S. Biotechs Sound the Alarm” on tariff impacts. The findings include: Tariffs on European Union and Canadian imports would increase manufacturing costs for 94% and 82% of biotech firms, respectively. 70% of companies anticipate higher manufacturing costs due to tariffs on China. Tariffs on the European Union would force 50% of biotech firms to identify new research and manufacturing partners. More than 50% of biotech firms predict “increased difficulty” in funding and conducting research if EU tariffs are enacted. 80% of biotech firms would need at least 12 months to find alternative suppliers; 44% would need over two years. The survey noted that sudden tariffs would fundamentally punish American companies, threaten vital research projects and imperil United States leadership in biomedical science. Read BIO’s press release , along with an one-pager summarizing the survey results. 

Amid Proposed Cuts, Commission Calls For $15B NIH Support

April 10, 2025
A federal commission, in a new report , is calling for $15 billion in new financing to reinforce the United States’ biotech leadership amid encroaching competition from China. This comes against a backdrop where the Trump Administration has proposed severe cuts to NIH operations and funding. The National Security Commission on Emerging Biotechnology was created by Congress in 2022 to explore how biotechnology advancements could shape the economy and national security. The body quickly focused on China, as that government has gone about gathering Americans’ genetic information and intellectual property in the biotech space and resourcing their cluster’s rapid growth. The report’s 49 recommendations, organized across six strategic pillars, offer a bold and actionable framework to protect U.S. biotech intellectual property and bolster drug development, agriculture, and biological weapons defense: Prioritize biotechnology at the national level Mobilize the private sector to get U.S. products to scale Maximize the benefits of biotechnology for defense Out-innovate our strategic competitors Build the biotechnology workforce of the future Mobilize the collective strengths of our allies and partners The report calls for $1 billion to create an investment fund, more than $6 billion for large-scale research challenges, and a build-up of biomanufacturing sites across the country. Also, it calls for new legislation barring companies that work with U.S. national security agencies or health agencies from using certain Chinese biotech suppliers. The commission doesn’t have the power to authorize any changes but can make recommendations and advise members of Congress. BIO issued a statement in support.